B7-33 2mg Pre-Mixed Peptide

Product Overview

B7-33 2mg Pre-Mixed Peptide, available exclusively through Direct Anti Peptide, is a high-purity synthetic peptide derived from the relaxin hormone family. This compound has attracted significant interest in the research community due to its demonstrated anti-fibrotic and cardioprotective properties in preclinical animal models. Fibrosis — the pathological accumulation of excess connective tissue — is implicated in a wide range of chronic and acute conditions, including heart failure, pulmonary inflammation, and renal disease. B7-33 has been studied for its capacity to reduce fibrotic progression and support tissue integrity, making it a compelling subject for researchers investigating organ protection and regenerative biology. Supplied in a convenient pre-mixed format, this peptide simplifies laboratory workflows and supports consistent, reproducible results across experimental settings.

Peptide Structure & Amino Acid Sequence

B7-33 is a single-chain peptide analogue of the B-chain of human relaxin-2 (H2 relaxin). Unlike full-length relaxin, B7-33 is engineered to selectively activate the RXFP1 receptor while avoiding activation of the cAMP signalling pathway, offering a more targeted pharmacological profile for research purposes. Its truncated, single-chain architecture makes it particularly valuable for studies focused on receptor-biased signalling and downstream fibrotic pathway modulation. The peptide is synthesised using solid-phase peptide synthesis (SPPS) methodology to ensure sequence fidelity and structural consistency across production batches.

Chemical & Physical Characteristics

• Peptide Name: B7-33
• Format: Pre-Mixed Peptide
• Peptide Class: Relaxin-derived synthetic analogue
• Target Receptor: RXFP1 (Relaxin Family Peptide Receptor 1)
• Purity: ≥98%
• Appearance: White to off-white lyophilised powder (pre-mixed in cartridge format)
• Solubility: Soluble in bacteriostatic water
• Storage Temperature: 2–8°C (refrigerated); protect from light and moisture

Purity & Analytical Verification (HPLC & MS)

Every batch of B7-33 2mg Pre-Mixed Peptide supplied by Direct Anti Peptide undergoes rigorous analytical testing to confirm identity and purity. High-Performance Liquid Chromatography (HPLC) is employed to verify that purity meets or exceeds the ≥98% threshold, while Mass Spectrometry (MS) confirms molecular weight accuracy and sequence integrity. These dual verification methods ensure that researchers receive a compound of consistent quality, suitable for demanding preclinical and in vitro research protocols. Certificates of Analysis (CoA) are available upon request and reflect batch-specific testing data.

Quality Control & Lyophilisation Integrity

The B7-33 peptide is produced under stringent quality control conditions and lyophilised to enhance long-term stability and shelf life. Lyophilisation removes moisture from the peptide matrix without compromising structural integrity, ensuring that the compound remains stable during transport and storage. In the pre-mixed format, the peptide cartridge is prepared under controlled conditions to maintain potency and reduce preparation time in the laboratory environment. Each unit is inspected prior to dispatch to confirm physical integrity and correct labelling.

Safety, Handling & Laboratory Precautions

B7-33 2mg Pre-Mixed Peptide is intended solely for use by trained research professionals operating within appropriately equipped laboratory environments. Standard laboratory safety protocols must be observed at all times, including the use of appropriate personal protective equipment (PPE) such as gloves, lab coat, and eye protection. This compound should be handled in accordance with institutional biosafety guidelines. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Researchers are responsible for ensuring compliance with all applicable local, national, and institutional regulations governing the use of research peptides.

Reconstitution, Packaging & Storage

The pre-mixed format of B7-33 2mg is supplied ready for laboratory use, with the peptide cartridge pre-combined with bacteriostatic water for researcher convenience. The full kit option available through Direct Anti Peptide includes the following components:

• 1 x Pre-Mixed Peptide Cartridge — containing B7-33 2mg combined with bacteriostatic water
• 1 x Peptide Cartridge Pen — precision delivery instrument for laboratory use
• 1 x Pen Carry Case — durable protective case for secure transport and storage
• 3 x Pen Needle Tips — compatible tips for use with the peptide pen system

Single pre-mixed cartridges are also available for researchers who already possess compatible pen delivery systems. Store all components between 2–8°C, away from direct light and humidity. Do not freeze the pre-mixed cartridge once combined.

Intended Research Use & Market Positioning

B7-33 is primarily studied in the context of fibrotic disease research, cardiovascular biology, and organ protection models. Preclinical animal studies have demonstrated its capacity to minimise fibrotic tissue accumulation, promote tissue regeneration and flexibility, and support improved survival outcomes following injury. Researchers in the fields of cardiac fibrosis, pulmonary disease, nephrology, and receptor-biased pharmacology will find B7-33 a highly relevant compound for advancing mechanistic understanding of RXFP1-mediated pathways. Direct Anti Peptide positions this product as a premium-grade research tool for serious laboratory investigators seeking reliable, analytically verified peptide compounds.

Ordering, Availability & Fulfillment

B7-33 2mg Pre-Mixed Peptide is available to buy online now through Direct Anti Peptide. Researchers can order the complete pen kit or a single pre-mixed cartridge depending on their laboratory requirements. We offer competitive best-price guarantees, secure checkout, and prompt order fulfillment to support uninterrupted research timelines. Orders are processed efficiently and dispatched with appropriate cold-chain packaging to preserve peptide integrity during transit. For bulk orders or institutional procurement enquiries, please contact our research sales team directly.

Legal & Regulatory Disclaimer

B7-33 2mg Pre-Mixed Peptide is sold strictly for in vitro and preclinical research purposes by Direct Anti Peptide. This product is not approved for human or veterinary administration and must not be used in any clinical, therapeutic, diagnostic, or consumptive context. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Purchasers are solely responsible for ensuring that their use of this compound complies with all applicable laws, regulations, and institutional policies in their jurisdiction. Direct Anti Peptide accepts no liability for misuse or unauthorised application of this research compound.